Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program
TheFly reported on April 7 that H.C. Wainwright reduced its price target on CVKD from $32 to $13 while maintaining a Buy rating.
Cadrenal Therapeutics Inc. (CVKD)
Market is closed
Sector: Healthcare
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.69 | 2,669 | $1,841.61 | 614,792 | 2023-10-05 | Filing | |
| $0.70 | 17,331 | $12,131.70 | 612,123 | 2023-10-04 | Filing | |
| $0.90 | 20,000 | $17,988.00 | 3,410,000 | 2023-09-05 | Filing | |
| $0.91 | 20,000 | $18,200.00 | 3,390,000 | 2023-09-05 | Filing | |
| $0.84 | 10,000 | $8,433.00 | 3,370,000 | 2023-09-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.93 | 2,989 | $14,735.77 | 182,161 | 2026-05-28 | Filing | |
| $5.28 | 3,298 | $17,413.44 | 185,150 | 2026-05-12 | Filing | |
| $5.76 | 6,476 | $37,301.76 | 188,448 | 2026-05-11 | Filing | |
| $5.69 | 1,165 | $6,628.85 | 194,924 | 2026-05-22 | Filing | |
| $6.97 | 9,933 | $69,233.01 | 0 | 2025-12-29 | Filing |
News See All
8 Oversold Biotech Stocks to Invest In Now
On February 5, J.P. Morgan revealed major themes that are expected to affect healthcare in 2026, emphasizing a resurgence of interest in the biopharma sector.
Hedge Fund Resource Center